What the FDA labels say about taking them together
Perindopril and temsirolimus
Perindopril's FDA label of March 13, 2024 names temsirolimus in its warnings and precautions section; temsirolimus's label does not name perindopril itself but warns about its class (ACE inhibitors). The perindopril label: “Patients taking concomitant mTOR inhibitor (e.g., temsirolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.9;”
Check it at the source: the perindopril FDA label on DailyMed (effective March 13, 2024, Aurobindo Pharma Limited); the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the perindopril label say about temsirolimus?
Perindopril label, warnings and precautionsPatients taking concomitant mTOR inhibitor (e.g., temsirolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.9 ;
Source: FDA drug label (Perindopril Erbumine), Aurobindo Pharma Limited, effective March 13, 2024 (SPL set 87768fbf-7c63-47da-8925-0316f343d6ef), via openFDA; the full label on DailyMed
What does the temsirolimus label say about perindopril?
Temsirolimus's label does not name perindopril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Perindopril | Temsirolimus | |
|---|---|---|
| Labeled for | High blood pressure, Heart attack and coronary artery disease | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.495 per tablet 4 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once